EGFR and non-small cell lung carcinoma: NSCLC patients with adenocarcinoma were also far more likely to carry the EGFR mutation (adenocarcinoma vs. non-adenocarcinoma: 38.0% vs. 11.7%; OR: 4.1, 95% CI: 3.6 to 4.8) in overall participants.